A team of researchers led by Luigi Naldini at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) has developed a ...

A team of researchers led by Luigi Naldini at the San Raffael Institute for Gene Therapy (SR-Tiget) has developed a new ...

Early CRISPR-based cholesterol therapy shows striking LDL reduction, but experts warn that safety, durability and off-target ...

Urnov is a professor of molecular therapeutics at the University of California, Berkeley, and a director at its Innovative Genomics Institute. In May, news broke of a biomedical first: the on-demand ...

The VERVE-102 base editor appeared to be safe and reduce low-density lipoprotein cholesterol levels by up to 62 percent in a Phase I open-label, single-ascending dose trial.

Novel CRISPR-Cas9 treatments are proving effective in reversing disease for life. But ensuring their long-term safety will ...

Precision gene editing can be achieved by base editing, nucleotide editing, or editing of small or large gene fragments. The specific mechanisms include various DNA repair pathways. Many precision ...

In what could be one of the biggest breakthroughs in treating heart disease, a small study showed that an experimental ...

Sickle-cell disease and β-thalassemia are inherited blood disorders that are caused by mutations in the HBB gene (encoding a component of adult hemoglobin) and are characterized by severe, lifelong ...

LDL Reduction: Studies have found that this therapy successfully reduced LDL cholesterol by up to 62 percent. Let's explain ...

Volatile macroeconomic events are magnified in life science and healthcare applications, which are capital intensive, long-term investments with associated regulatory, safety, and commercial risks.